Skip to main content

Table 2 Akaike Information Criterion (AIC) values for the Cox models, First 6 months of follow-up (464 patients)

From: Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study

Model

 

HR (95% CI)

p value

AIC*

RECIST

Partial response

1

 

575.762

 

Stable disease

2.29 (1.06-4.94)

0.03

 
 

Progressive disease

18.48 (8.41-40.59)

<10−4

 

UCSTS

per 10% difference

1.21 (1.16-1.26)

<10−4

578.585

  1. The analysis was routinely adjusted on histology and cancer spread. Sex and chemotherapy doublet were proposed to the model but not kept at the final step. The analysis was stratified on ECOG-PS and hospital.
  2. *In the model with RECIST, −2log likelihood = 563.762 with 6 degrees of freedom. In the model with UCSTS changes, −2log likelihood = 568.585 with 5 degrees of freedom.
  3. p = 0.03.
  4. HR, hazard ratio; 95% CI, 95% confidence interval; RECIST, Response Evaluation Criteria in Solid Tumors; UCSTS, unidimensional continuous-scale tumour size.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us